54 completed, 11 unknown, 10 not yet recruiting, 7 active not recruiting. 24 Not applicable, 20 Phase 2, 17 Phase 1, 15 Phase 3, 2 Early Phase 1.
Follow Alphavirus Infections: new trials by email Literature Review of Alphavirus Infections trials Research Report on Alphavirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Against Chikungunya Virus and Neonatal Infection plasma transfusion : PC-CHIK-V - Chikungunya Virus Infection, Neonatal | Not applicable | Recruiting | Centre Hospitalier Universitaire de la Réunion | 60 | 2027-08-01 | 2026-09-15 |
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Evaluation of IXCHIQ® Vaccine Immunogenicity IXCHIQ vaccine - Healthy Adult, Healthy Adolescents | Phase 2 | Not yet recruiting | Mauro Martins Teixeira | 75 | 2026-09-24 | 2026-09-29 |
| Smart Analysis and Decision-Making for Emerging Infectious Diseases Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19 | Not applicable | Enrolling by invitation | Peking University | 108 | 2026-08-10 | 2026-08-19 |
| A Phase I Study of PepGNP-ChikV in Healthy Volunteers PepGNP-ChikV, Placebo - Chikungunya, Chikungunya Fever | Early Phase 1 | Not yet recruiting | Gylden Pharma Ltd | 40 | 2026-08-03 | 2026-04-29 |
| Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients Exercise - Dengue, Chikungunya | Not applicable | Not yet recruiting | Universidade do Estado do Pará | 54 | 2026-07-01 | 2026-05-26 |
| VLA1553-403 Pregnancy Surveillance Study Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH - Chikungunya Virus Infection | Enrolling by invitation | Valneva Austria GmbH | 200 | 2026-06-11 | 2026-07-20 | |
| An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults CHIKV VLP vaccine, Placebo - Chikungunya Virus | Phase 3 | Recruiting | Bavarian Nordic | 6144 | 2026-05-26 | 2026-11-13 |
| A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age. BBV87 Chikungunya vaccine, Placebo - Active Immunisation for Chikungunya Virus Infection | Phase 2 / Phase 3 | Recruiting | Bharat Biotech International Limited | 1000 | 2026-04-20 | 2026-04-29 |
| Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities Full intervention, Partial intervention - Dengue, Zika | Not applicable | Completed | University of Freiburg | 900 | 2026-03-26 | 2026-04-08 |
| A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children VLA1553, Control - Chikungunya Virus Infection | Phase 3 | Withdrawn | Valneva Austria GmbH | 2026-02-06 | 2025-12-31 | |
| Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection | Active not recruiting | Valneva Austria GmbH | 5000 | 2026-02-02 | 2026-07-21 | |
| Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection | Enrolling by invitation | Valneva Austria GmbH | 1200 | 2026-02-02 | 2026-07-17 | |
| Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya | Recruiting | Institut Pasteur du Cambodge | 10000 | 2025-12-18 | 2026-01-22 | |
| Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection | Active not recruiting | Valneva Austria GmbH | 5354 | 2025-09-22 | 2026-02-11 | |
| Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections Exanthema, Dengue Fever | Not yet recruiting | Hospital Israelita Albert Einstein | 830 | 2025-09-01 | 2025-08-08 | |
| A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever Reduning injection, The simulant of Reduning Injection - Chikungunya Fever | Not applicable | Not yet recruiting | Jiangsu Kanion Pharmaceutical Co., Ltd | 400 | 2025-08-28 | 2025-08-17 |
| Xpert® Tropical Fever Test on GeneXpert® Edge X System Xpert Tropical Fever test - Malaria Fever, Zika | Enrolling by invitation | Cepheid | 2500 | 2025-08-18 | 2026-04-09 | |
| A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers V4020 - Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection | Phase 1 | Not yet recruiting | Medigen, Inc. | 39 | 2025-08-15 | 2025-07-28 |
| The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons - Arbovirus Infections | Active not recruiting | University Hospital, Strasbourg, France | 200 | 2025-08-01 | 2025-08-08 |
Showing 20 of 103. Sign in to see all of them.
Chikungunya Fever (88) · Dengue (31) · Zika Virus Infection (27) · Encephalomyelitis, Venezuelan Equine (8) · Malaria (8) · Arbovirus Infections (7) · Encephalitis (4) · Leptospirosis (4) · Vector Borne Diseases (4) · Virus Diseases (4) · Communicable Diseases (3) · Encephalomyelitis, Eastern Equine (3) · Encephalomyelitis, Equine (3) · Leishmaniasis (3)
Infections (103) · RNA Virus Infections (102) · Togaviridae Infections (102) · Mosquito-Borne Diseases (101) · Vector Borne Diseases (99) · Virus Diseases (99) · Arbovirus Infections (96) · Flaviviridae Infections (35) · Flavivirus Infections (34) · Hemorrhagic Fevers, Viral (31) · Central Nervous System Diseases (16) · Nervous System Diseases (16) · Neuroinflammatory Diseases (16) · Brain Diseases (15)
Blood Specimen Collection (5) · Desiccation (3) · Vaccines (3) · Exercise (2) · Measles-Mumps-Rubella Vaccine (2) · Seeds (2) · Arthrocentesis (1) · Chloroquine (1) · Dosage Forms (1) · Educational Status (1) · Neuropsychological Tests (1) · Observation (1) · Phlebotomy (1) · Resistance Training (1) · Reverse Transcriptase Polymerase Chain Reaction (1)
Valneva Austria GmbH (11) · Bavarian Nordic (9) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Centre Hospitalier Universitaire de la Réunion (6) · U.S. Army Medical Research and Development Command (6) · Themis Bioscience GmbH (4) · Institut Pasteur (3) · Bharat Biotech International Limited (2) · Butantan Institute (2) · Centre Hospitalier Universitaire de la Guadeloupe (2) · Kaohsiung Medical University Chung-Ho Memorial Hospital (2) · University Hospital Center of Martinique (2) · University of Heidelberg Medical Center (2) · University of Notre Dame (2) · University of Oxford (2)
United States (31) · Brazil (14) · France (10) · Colombia (6) · Mexico (5) · Reunion (5) · Germany (4) · Guadeloupe (4) · Puerto Rico (4) · Cambodia (3) · China (3) · French Guiana (3) · Austria (2) · Belgium (2) · Dominican Republic (2)
Myrielle Dupont-Rouzeyrol, PhD (3) · Andre Cabie, MD (2) · Anthony Cardile, DO (2) · Clemente Diaz, MD (2) · Grace Chen, MD (2) · James McCarty, MD (2) · Patrick Ajiboye, MD (2) · Robert Rivard, MD (2) · Adi Utarini, MD, PhD (1) · Adrian V Hill, DPhill FRCP (1) · Aileen Y Chang, MD MSPH (1)
PMID 35709798, PMID 31878895, PMID 32497524, PMID 33422034, PMID 37254133, PMID 37321235, PMID 25132507, PMID 25739878, PMID 27206386, PMID 27694629, PMID 27705091, PMID 29266856, PMID 29855331, PMID 30409443, PMID 30572920, PMID 31672665, PMID 32163420, PMID 32220283, PMID 32286643, PMID 32450914, PMID 33686914, PMID 33828518, PMID 33836004, PMID 33899755, PMID 34107180, PMID 34330906, PMID 34454432, PMID 34529649, PMID 34582377, PMID 34718636, PMID 34887572, PMID 34900237, PMID 35210606, PMID 35236394, PMID 35255839, PMID 35568049, PMID 36384430, PMID 37068115, PMID 37690874, PMID 38032857, PMID 38294972, PMID 38494412, PMID 38794811, PMID 39004524, PMID 39067885, PMID 39116904, PMID 39146946, PMID 39243794, PMID 39255380, PMID 39297691
2014 (1), 2015 (1), 2018 (1), 2025 (1), U01AI148069 (1), U44AI152995 (1)